Background

OptiMalVax is a Collaborative Project on malaria vaccine development funded by the European Union’s Horizon 2020 Programme and coordinated by the Jenner Institute at the University of Oxford.

A highly effective malaria vaccine against the causative parasite Plasmodium falciparum should help prevent half a million deaths from malaria each year.

New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible.

Leading malariologists, vaccine researchers and product developers will here collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates.